- Home
- ABOS vs TARA Comparison
ABOS vs TARA Comparison
Compare ABOS & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABOS | TARA |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.9M | 236.1M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ABOS | TARA |
|---|---|---|
| Price | $2.24 | $4.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $8.00 | ★ $24.40 |
| AVG Volume (30 Days) | 353.9K | ★ 453.8K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $2.97 |
| 52 Week High | $3.60 | $7.82 |
Technical Indicators
Market Signals| Indicator | ABOS | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | 46.06 |
| Support Level | $2.13 | $3.69 |
| Resistance Level | $2.43 | $4.23 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 53.33 | 47.56 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.